FOXP3 and acute myeloid leukemia: The results showed that the percentage of NKG2D+Foxp3− non-Vδ1/Vδ2 T cells was significantly reduced in both the AML-DN group (median: 26.80% vs. 71.30%, p < 0.001) and the CR group (median: 39.80% vs. 71.30%, p = 0.001) compared to HIs.